Pancreatic Cancer

ClinicalJuly 31, 2026

Cost-effectiveness of Tumor Treating Fields in Advanced Pancreatic Cancer Evaluated

The PANOVA-3 trial shows that Tumor Treating Fields combined with gemcitabine and nab-paclitaxel improves overall survival and progression-free survival in locally advanced pancreatic cancer patients.

Companies

Assets

Recent signals(15)

Lilly's olomorasib receives FDA Breakthrough Therapy designation for advanced pancreatic cancer

Cost-effectiveness of Tumor Treating Fields in Advanced Pancreatic Cancer Evaluated

Phase I Trial of Durvalumab and Olaparib with Radiation for Unresectable Pancreatic Cancer

DN022150 Trial Initiated for Advanced Pancreatic Cancer with KRAS G12D Mutation

Phase 1/2 Study of Gemcitabine/Nab-paclitaxel and Radiation in Advanced Pancreatic Cancer

Surufatinib Combination Trial for High-Risk Pancreatic Cancer Initiated

New Workflow for Isolating Microbiota from Pancreatic Tumors and Duodenum

Advancements in Single-Cell and Spatial Transcriptomics for Pancreatic Cancer Insights

UBE2C identified as a key driver in pancreatic cancer via PI3K/Akt/mTOR pathway

Phase Ib/II Study of Becotatugvedotin with Gemcitabine in Advanced PDAC

Study on Predictive Model for Pancreatic Cancer Prognosis Using Multimodal Data

Study on Blood Markers for Early Detection of Pancreatic Cancer Initiated

Study Links Chronic Psychological Stress to Outcomes in Pancreatic Cancer

Pilot Study on Targeted Physical Activity in Pancreatic Cancer Patients Undergoing Chemotherapy

Non-coding RNAs as regulators of aerobic glycolysis in pancreatic ductal adenocarcinoma

Upcoming catalysts

Indications

Get signals before the market moves